# AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

> **NCT03127449** · NA · TERMINATED · sponsor: **Allist Pharmaceuticals, Inc.** · enrollment: 116 (actual)

## Conditions studied

- Advanced NSCLC

## Interventions

- **DRUG:** Alflutinib

## Key facts

- **NCT ID:** NCT03127449
- **Lead sponsor:** Allist Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-01
- **Primary completion:** 2021-05-12
- **Final completion:** 2024-01-08
- **Target enrollment:** 116 (ACTUAL)
- **Why stopped:** Indications have been approved for marketing
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03127449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03127449, "AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03127449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*